Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

Kidney Cancer
doi 10.3233/kca-180049
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IOS Press

Related search

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

The Effect of Everolimus and Low-Dose Cyclophosphamide on Immune Cell Subsets in Patients With Metastatic Renal Cell Carcinoma: Results From a Phase I Clinical Trial

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Outcomes Based on Age in the Phase III METEOR Trial of Cabozantinib Versus Everolimus in Patients With Advanced Renal Cell Carcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Cost Utility Analysis of Everolimus in the Treatment of Metastatic Renal Cell Cancer in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Neo-Adjuvant Chemo/Immunotherapy in the Treatment of Stage III (N2) Non-Small Cell Lung Cancer: A Phase I/Ii Pilot Study

International Journal of Immunopathology and Pharmacology
AllergyImmunologyPharmacology
2011English

Everolimus &Ndash; A New Approach in the Treatment of Renal Cell Carcinoma

Cancer Management and Research
Oncology
2010English

Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Increase in Spleen Volume as a Predictor of Oxaliplatin Toxicity

Therapeutics and Clinical Risk Management
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy